139 related articles for article (PubMed ID: 31431711)
21. NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation.
Wu X; Sharma A; Oldenburg J; Weiher H; Essler M; Skowasch D; Schmidt-Wolf IGH
Front Immunol; 2021; 12():731767. PubMed ID: 34691037
[TBL] [Abstract][Full Text] [Related]
22. Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion.
Rettinger E; Kreyenberg H; Merker M; Kuçi S; Willasch A; Bug G; Ullrich E; Wels WS; Bonig H; Klingebiel T; Bader P
Cytotherapy; 2014 Jun; 16(6):835-44. PubMed ID: 24582456
[TBL] [Abstract][Full Text] [Related]
23. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
[TBL] [Abstract][Full Text] [Related]
24. Phenotypic and functional characterisation of locally produced natural killer cells ex vivo expanded with the K562-41BBL-mbIL21 cell line.
Shman TV; Vashkevich KP; Migas AA; Matveyenka MA; Lasiukov YA; Mukhametshyna NS; Horbach KI; Aleinikova OV
Clin Exp Med; 2023 Oct; 23(6):2551-2560. PubMed ID: 36527513
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.
Cappel C; Huenecke S; Suemmerer A; Erben S; Rettinger E; Pfirrmann V; Heinze A; Zimmermann O; Klingebiel T; Ullrich E; Bader P; Bremm M
Pediatr Blood Cancer; 2016 Dec; 63(12):2230-2239. PubMed ID: 27433920
[TBL] [Abstract][Full Text] [Related]
26. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
[TBL] [Abstract][Full Text] [Related]
27. Phenotypic characterization and anticancer capacity of CD8+ cytokine-induced killer cells after antigen-induced expansion.
Liu J; Wang L; Wang Y; Zhang W; Cao Y
PLoS One; 2017; 12(4):e0175704. PubMed ID: 28426690
[TBL] [Abstract][Full Text] [Related]
28. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
29. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
Björklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikström K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellström-Lindberg E; Ljunggren HG; Malmberg KJ
Clin Cancer Res; 2018 Apr; 24(8):1834-1844. PubMed ID: 29444931
[No Abstract] [Full Text] [Related]
30. Haploidentical Stem Cell Transplantation in Children With Hematological Malignancies Using αβ
Diaz MA; Zubicaray J; Molina B; Abad L; Castillo A; Sebastian E; Galvez E; Ruiz J; Vicario JL; Ramirez M; Sevilla J; González-Vicent M
Front Immunol; 2019; 10():2504. PubMed ID: 31736949
[TBL] [Abstract][Full Text] [Related]
31. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
32. CIK as therapeutic agents against tumors.
Introna M
J Autoimmun; 2017 Dec; 85():32-44. PubMed ID: 28679475
[TBL] [Abstract][Full Text] [Related]
33. Safety and immune cell kinetics after donor natural killer cell infusion following haploidentical stem cell transplantation in children with recurrent neuroblastoma.
Choi YB; Son MH; Cho HW; Ma Y; Lee JW; Kang ES; Yoo KH; Her JH; Lim O; Jung M; Hwang YK; Sung KW; Koo HH
PLoS One; 2019; 14(12):e0225998. PubMed ID: 31834883
[TBL] [Abstract][Full Text] [Related]
34. Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells.
Bremm M; Pfeffermann LM; Cappel C; Katzki V; Erben S; Betz S; Quaiser A; Merker M; Bonig H; Schmidt M; Klingebiel T; Bader P; Huenecke S; Rettinger E
Front Immunol; 2019; 10():1218. PubMed ID: 31214182
[TBL] [Abstract][Full Text] [Related]
35. Immunophenotype and antitumor activity of cytokine-induced killer cells from patients with hepatocellular carcinoma.
Yang CK; Huang CH; Hu CH; Fang JH; Chen TC; Lin YC; Lin CY
PLoS One; 2023; 18(1):e0280023. PubMed ID: 36598909
[TBL] [Abstract][Full Text] [Related]
36. [The cytotoxicity of CIK/NK cells stimulated by K562-DC fusion vaccines in NOD/SCID mice model for human erythroleukemia].
Li Y; Huang SL; Zhang XC; Fang JP; Wu YF; Wei J; Huang WG; Zhou DH; Huang K; Lin YC
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):39-43. PubMed ID: 18512314
[TBL] [Abstract][Full Text] [Related]
37. Multivariate statistical data analysis as a tool to analyze ex vivo expansion dynamics of cytokine-induced killer cells.
Zanon C; Stocchero M; Albiero E; Castegnaro S; Chieregato K; Madeo D; Rodeghiero F; Astori G
Cytometry B Clin Cytom; 2014 Jul; 86(4):257-62. PubMed ID: 24002818
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
[TBL] [Abstract][Full Text] [Related]
39. Preparation of Cytokine-activated NK Cells for Use in Adoptive Cell Therapy in Cancer Patients: Protocol Optimization and Therapeutic Potential.
van Ostaijen-ten Dam MM; Prins HJ; Boerman GH; Vervat C; Pende D; Putter H; Lankester A; van Tol MJ; Zwaginga JJ; Schilham MW
J Immunother; 2016; 39(2):90-100. PubMed ID: 26849078
[TBL] [Abstract][Full Text] [Related]
40. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation.
Ciurea SO; Schafer JR; Bassett R; Denman CJ; Cao K; Willis D; Rondon G; Chen J; Soebbing D; Kaur I; Gulbis A; Ahmed S; Rezvani K; Shpall EJ; Lee DA; Champlin RE
Blood; 2017 Oct; 130(16):1857-1868. PubMed ID: 28835441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
